Cortactin gene amplification and expression in breast cancer: a chromogenic in situ hybridisation and immunohistochemical study

Amplification of 11q13 is found in approximately 15% of breast cancers. Cyclin D1 (CCND1) has been reported to be the ‘driver’ of this amplicon, however, multiple genes map to the smallest region of amplification of 11q13. Out of these genes, cortactin (CTTN) has been shown to be consistently overexpressed at the mRNA level in tumours harbouring 11q13 amplification. The aims of this study are to define whether CTTN is consistently co-amplified with the main core of the 11q13 amplicon, whether it is consistently overexpressed when amplified and to determine correlations between CTTN amplification and overexpression with clinicopathological features of breast cancers and survival of breast cancer patients. CTTN and CCND1 chromogenic in situ hybridisation (CISH) probes and a validated monoclonal antibody against CTTN were applied to a tissue microarray of a cohort of breast cancers from patients treated with anthracycline-based chemotherapy. CTTN and CCND1 amplifications were found in 12.3 and 12.4% of cases, respectively. All cases harbouring CTTN amplification also displayed CCND1 amplification. High expression of CTTN was found in 10.8% of cases and was associated with CTTN amplification, expression of ‘basal’ markers and topoisomerase IIα. Exploratory subgroup analysis of tumours devoid of 11q13 amplification revealed that high expression of CTTN in the absence of CTTN gene amplification was associated with lymph node negative disease, lack of hormone receptors and FOXA1, expression of ‘basal’ markers, high Ki-67 indices, p53 nuclear expression, and basal-like and triple negative phenotypes. CTTN expression and CTTN gene amplification were not associated with disease-, metastasis-free and overall survival. In conclusion, CTTN is consistently co-amplified with CCND1 and expressed at higher levels in breast cancers harbouring 11q13 amplification, suggesting that CTTN may also constitute one of the drivers of this amplicon. CTTN expression is not associated with the outcome of breast cancer patients treated with anthracycline-based chemotherapy.

[1]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. , 1999, Critical reviews in oncology/hematology.

[2]  R. Zeillinger,et al.  Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. , 1997, Cancer research.

[3]  S. Weed,et al.  Cortactin branches out: roles in regulating protrusive actin dynamics. , 2008, Cell motility and the cytoskeleton.

[4]  A. Ashworth,et al.  Tiling Path Genomic Profiling of Grade 3 Invasive Ductal Breast Cancers , 2009, Clinical Cancer Research.

[5]  J. Reis-Filho,et al.  Reduction of E-cadherin expression is associated with non-lobular breast carcinomas of basal-like and triple negative phenotype , 2007, Journal of Clinical Pathology.

[6]  K. Jirström,et al.  Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. , 2005, Cancer research.

[7]  D. Birnbaum,et al.  BMC Cancer , 2003 .

[8]  D. Yu,et al.  Upregulation and activation of PKCα by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKCα and Src inhibitors , 2006, Oncogene.

[9]  J. Dering,et al.  Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro , 2007, Breast Cancer Research and Treatment.

[10]  J. Reis-Filho,et al.  Nestin is expressed in basal-like and triple negative breast cancers , 2008, Journal of Clinical Pathology.

[11]  C. Haudenschild,et al.  Cortactin potentiates bone metastasis of breast cancer cells. , 2001, Cancer research.

[12]  C Caldas,et al.  Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers , 2007, Oncogene.

[13]  Andrew R. Green,et al.  CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome , 2008, Breast Cancer Research and Treatment.

[14]  Alissa M. Weaver.  Cortactin in tumor invasiveness. , 2008, Cancer letters.

[15]  E. Schuuring,et al.  Identification and cloning of two overexpressed genes, U21B31/PRAD1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas. , 1992, Oncogene.

[16]  Å. Borg,et al.  Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer , 2008, Breast Cancer Research.

[17]  J. Reis-Filho,et al.  Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis , 2007, Journal of Clinical Pathology.

[18]  A. Ashworth,et al.  An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers , 2010, Breast Cancer Research and Treatment.

[19]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[20]  D. Horsfall,et al.  EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer , 1997, Oncogene.

[21]  A. Ashworth,et al.  Mixed micropapillary–ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components , 2009, The Journal of pathology.

[22]  S. Jeffrey,et al.  Focal amplification and oncogene dependency of GAB2 in breast cancer , 2010, Oncogene.

[23]  S Detre,et al.  A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. , 1995, Journal of clinical pathology.

[24]  S. Weed,et al.  Cortactin: coupling membrane dynamics to cortical actin assembly , 2001, Oncogene.

[25]  M. Mottolese,et al.  Bio-pathologic Characteristics Related to Chromosome 11 Aneusomy and Cyclin D1 Gene Status in Surgically Resected Stage I and II Breast Cancer: Identification of an Adverse Prognostic Profile , 2007, The American journal of surgical pathology.

[26]  S. Weed,et al.  Cortactin Is a Functional Target of E-cadherin-activated Src Family Kinases in MCF7 Epithelial Monolayers* , 2009, The Journal of Biological Chemistry.

[27]  J. Pollack,et al.  RNA interference‐based functional dissection of the 17q12 amplicon in breast cancer reveals contribution of coamplified genes , 2006, Genes, chromosomes & cancer.

[28]  M. Fresno,et al.  Distinctive clinicopathological associations of amplification of the cortactin gene at 11q13 in head and neck squamous cell carcinomas , 2009, The Journal of pathology.

[29]  Robin L. Jones,et al.  Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis , 2006, Modern Pathology.

[30]  S. Culine,et al.  Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. , 2000, Cancer research.

[31]  J. Forbes,et al.  EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival , 1998, Oncogene.

[32]  Marketa Zvelebil,et al.  PPM1D Is a Potential Therapeutic Target in Ovarian Clear Cell Carcinomas , 2009, Clinical Cancer Research.

[33]  Fei Huang,et al.  Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. , 2007, Cancer research.

[34]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[35]  C. Purdie,et al.  High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer , 2010, International journal of cancer.

[36]  T. Oyama,et al.  Frequent overexpression of the cyclin D1 oncogene in invasive lobular carcinoma of the breast. , 1998, Cancer research.

[37]  S. Weed,et al.  Cortactin overexpression regulates actin-related protein 2/3 complex activity, motility, and invasion in carcinomas with chromosome 11q13 amplification. , 2006, Cancer research.

[38]  Robin L. Jones,et al.  Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis , 2008, Breast Cancer Research and Treatment.

[39]  Peter Schraml,et al.  Prognostic Relevance of Gene Amplifications and Coamplifications in Breast Cancer , 2004, Cancer Research.

[40]  S. Tavaré,et al.  High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer , 2007, Genome Biology.

[41]  Tsutomu Ohta,et al.  Overexpression of cortactin is involved in motility and metastasis of hepatocellular carcinoma. , 2004, Journal of hepatology.

[42]  J. Rodrigo,et al.  EMS1 gene amplification correlates with poor prognosis in squamous cell carcinomas of the head and neck. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  S. Singletary,et al.  Breast Cancer Staging: Working With the Sixth Edition of the AJCC Cancer Staging Manual , 2006, CA: a cancer journal for clinicians.

[44]  G. Corthals,et al.  A Cortactin-CD2-associated Protein (CD2AP) Complex Provides a Novel Link between Epidermal Growth Factor Receptor Endocytosis and the Actin Cytoskeleton* , 2003, Journal of Biological Chemistry.

[45]  J. Fridlyand,et al.  Co-amplified genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis , 2009, Oncogene.

[46]  A. Ouhtit,et al.  Cortactin underpins CD44-promoted invasion and adhesion of breast cancer cells to bone marrow endothelial cells , 2006, Oncogene.

[47]  A. Ashworth,et al.  Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization , 2006, Laboratory Investigation.

[48]  Alissa M. Weaver,et al.  Aggressiveness of HNSCC tumors depends on expression levels of cortactin, a gene in the 11q13 amplicon , 2008, Oncogene.

[49]  Robert L. Sutherland,et al.  Cyclin D1, EMS1 and 11q13 Amplification in Breast Cancer , 2003, Breast Cancer Research and Treatment.

[50]  A. Ashworth,et al.  A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines , 2009, Breast Cancer Research and Treatment.

[51]  A. Ashworth,et al.  The genomic profile of HER2‐amplified breast cancers: the influence of ER status , 2008, The Journal of pathology.

[52]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[53]  M. J. van de Vijver,et al.  Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. , 1992, Cancer research.

[54]  C. Theillet,et al.  Comparative genomic hybridization analysis of breast tumors with predetermined profiles of DNA amplification. , 1997, Cancer research.

[55]  S. Roychoudhury,et al.  Analysis of Different Deleted Regions in Chromosome 11 and Their Interrelations in Early- and Late-Onset Breast Tumors: Association with Cyclin D1 Amplification and Survival , 2004, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[56]  Q. Zhan,et al.  Amplification and overexpression of CTTN (EMS1) contribute to the metastasis of esophageal squamous cell carcinoma by promoting cell migration and anoikis resistance. , 2006, Cancer research.

[57]  Robin L. Jones,et al.  Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients , 2008, Breast Cancer Research and Treatment.

[58]  Carlos Caldas,et al.  Identification and validation of prognostic markers in breast cancer with the complementary use of array‐CGH and tissue microarrays , 2005, The Journal of pathology.

[59]  A. Ashworth,et al.  Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast , 2008, The Journal of pathology.

[60]  J. Reis-Filho,et al.  CD44 is overexpressed in basal-like breast cancers but is not a driver of 11p13 amplification , 2010, Breast Cancer Research and Treatment.

[61]  N. Guevara,et al.  Prognostic significance of cortactin levels in head and neck squamous cell carcinoma: comparison with epidermal growth factor receptor status , 2008, British Journal of Cancer.

[62]  D. Thomas,et al.  An invasion-related complex of cortactin, paxillin and PKCμ associates with invadopodia at sites of extracellular matrix degradation , 1999, Oncogene.